MARKET

ARWR

ARWR

Arrowhead Pharma
NASDAQ
66.39
-0.86
-1.28%
After Hours: 67.58 +1.19 +1.79% 19:17 12/31 EST
OPEN
66.51
PREV CLOSE
67.25
HIGH
67.26
LOW
66.00
VOLUME
1.07M
TURNOVER
--
52 WEEK HIGH
72.36
52 WEEK LOW
9.57
MARKET CAP
9.02B
P/E (TTM)
-5441.8033
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR) and Evolus (EOLS)
TipRanks · 12/31/2025 11:40
Arrowhead Pharmaceuticals Director Mauro Ferrari Reports Disposal of Common Shares
Reuters · 12/30/2025 22:47
My Market Outlook For 2026: Focus On Pharma For Consistent Returns, Potential Skyrocketing Shares
Seeking Alpha · 12/29/2025 16:00
iShares Core S&P Small-Cap ETF Experiences Big Outflow
NASDAQ · 12/29/2025 15:49
Weekly Report: what happened at ARWR last week (1222-1226)?
Weekly Report · 12/29/2025 10:16
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After FDA Breakthrough Status for Plozasiran and Redemplo Launch
Simply Wall St · 12/25/2025 04:53
Arrowhead Pharmaceuticals CFO William D. Waddill Reports Sale of Common Shares
Reuters · 12/23/2025 23:02
Arrowhead Pharmaceuticals Director Victoria Vakiener Reports Sale of Common Shares
Reuters · 12/23/2025 23:02
More
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.

Webull offers Arrowhead Pharmaceuticals Inc stock information, including NASDAQ: ARWR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARWR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ARWR stock methods without spending real money on the virtual paper trading platform.